Related Articles
Clinical Trial Experiences of Patients
US Myozyme Manufacturing Update - April 2008
Genzyme Provides Update on Myozyme® Manufacturing
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
January 2008 US Myozyme Supply Update
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
OCTOBER UPDATE ON US MYOZYME®SUPPLY
REHABILITATION MANAGEMENT OF POMPE DISEASE: GREGORY T. CARTER, MD, MS
JOINT LETTER FROM THE AMDA AND UPF
MYOZYME® TEMPORARY ACCESS PROGRAM (MTAP) UPDATES
WSJ LETTER TO THE EDITOR
US MYOZYME® SUPPLY UPDATE JULY 25, 2007
MTAP FACT SHEET JULY 2007
GENZYME POMPE PROGRAM UPDATE JUNE 2007
MTAP FACT SHEET JUNE 2007
POMPE PROGRAM UPDATE MAY 2007
MYOZYME® TEMPORARY ACCESS PROGRAM
ILLINOIS NEWBORN SCREENING/SENATE BILL 1566
GENZYME POMPE PROGRAM UPDATE APRIL 2007
GENZYME UPDATE ON THE LOTS TRIAL- JANUARY 2007
AMICUS THERAPEUTICS COMMENCES PHASE 1 CLINICAL TRIALS FOR AT2220 FOR POMPE DISEASE
THE MYOZYME MIRACLE
FDA APPROVES GENZYMES MYOZYME® FOR ALL PATIENTS WITH POMPE DISEASE
Expensive drug gives hope to rare disease sufferer
ANGEL FLIGHT NORTHEAST GROUP
ANGEL FLIGHT AIR TRANSPORT
FLYING WITH A VENTILATOR IN THE USA
Association for Glycogen Storage Disease
JUAN MAGDARAOG BLOG
Canadian Association of Pompe
Myozyme Home Page
EXPRESSION OF HOPE
Amicus Therapeutics
UK Pompe Group
Helping Hands Loving Hearts
International Pompe Association IPA
Clinical Trial Information
Genzyme's Pompe Website
